Short interest up a bit
Gotta have big kahooonies to feel confident shorting such an unpredictable stock.
Know the swings I suppose.
Vericel Corporation (NASDAQ:VCEL) had an increase of 1.61% in short interest. VCEL’s SI was 6.13 million shares in August as released by FINRA. Its up 1.61% from 6.03M shares previously. With 576,400 avg volume, 11 days are for Vericel Corporation (NASDAQ:VCEL)’s short sellers to cover VCEL’s short positions. The stock decreased 2.63% or $0.49 during the last trading session, reaching $18.11. About 579,405 shares traded or 15.89% up from the average. Vericel Corporation (NASDAQ:VCEL) has risen 91.20% since August 8, 2018 and is uptrending. It has outperformed by 91.20% the S&P500. Some Historical VCEL News: 08/05/2018 – Vericel 1Q Loss/Shr 21c; 11/05/2018 – PNC Financial Services Group Buys New 1.7% Position in Vericel; 30/05/2018 – Vericel Corp Announces Proposed Public Offering of Common Stk; 14/05/2018 – Next Century Growth Investors Buys New 1% Position in Vericel; 17/05/2018 – Vericel 31.3% Owned by Hedge Funds; 23/03/2018 – Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years; 05/04/2018 – Vericel Investor Day Scheduled By Trout Group for Apr. 11; 20/04/2018 – DJ Vericel Corporation, Inst Holders, 1Q 2018 (VCEL); 12/03/2018 Vericel to Host Analyst and Investor Day on April 11, 2018
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $795.23 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Among 2 analysts covering Vericel Corp (NASDAQ:VCEL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 9 analyst reports since February 26, 2019 according to SRatingsIntel. Oppenheimer maintained Vericel Corporation (NASDAQ:VCEL) on Tuesday, February 26 with “Buy” rating. Oppenheimer maintained the stock with “Buy” rating in Thursday, March 7 report. BTIG Research maintained the shares of VCEL in report on Thursday, June 20 with “Buy” rating. On Tuesday, February 26 the stock rating was maintained by BTIG Research with “Buy”.
